The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 14, 2023

Filed:

Aug. 01, 2017
Applicants:

Immunolight, Llc, Detroit, MI (US);

Duke University, Durham, NC (US);

Inventors:

Harold Walder, Belville, NC (US);

Frederic A. Bourke, Jr., Aspen, CO (US);

Zakaryae Fathi, Raleigh, NC (US);

Wayne Beyer, Bahama, NC (US);

Mark Oldham, Durham, NC (US);

Justus Adamson, Durham, NC (US);

Paul Yoon, Durham, NC (US);

Assignees:

IMMUNOLIGHT, LLC, Detroit, MI (US);

DUKE UNIVERSITY, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01); A61K 41/00 (2020.01); A61K 33/42 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61N 5/062 (2013.01); A61K 33/42 (2013.01); A61K 41/00 (2013.01); A61K 41/0057 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); A61N 2005/1098 (2013.01);
Abstract

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.


Find Patent Forward Citations

Loading…